Response of infantile hepatic hemangioma to propranolol resistant to high‐dose methylprednisolone and interferon‐α therapy

Sarıalıoğlu, Faık; Erbay, Ayşe; Demır, Şenay

doi:10.1002/pbc.22691

Cited by 39 publications

(23 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intermediate effects are due to the blocking of proangiogenic signals (vascular endothelial growth factor, basic fibroblast growth factor, and matrix metalloproteinase 9) and result in growth arrest. Long-term effects of propranolol are characterized by induction of apoptosis in proliferating endothelial cells and result in tumor regression (Storch and Hoeger 2010;Léauté-Labrèze et al 2008;Sarialioglu et al 2010;Sans et al 2009;Buckmiller et al 2010). Our data in agreement with each other revealed that propranolol inhibited proliferation of U266 human multiple myeloma cells in a time-and dose-dependent manner.…”

Section: Discussionsupporting

confidence: 81%

“…The contribution of b-adrenergic receptor functions to tumorigenesis was also reflected by the suggested antiangiogenic effects of b-blockers on a tumor-associated endothelial cell model (Park et al 1995;Annabi et al 2009;Sidbury 2010;Sommers Smith and Smith 2002). Propranolol may revolutionize the treatment for problematic hemangiomas that cause imminent functional or cosmetic sequelae (Storch and Hoeger 2010;Léauté-Labrèze et al 2008;Sarialioglu et al 2010;Sans et al 2009;Buckmiller et al 2010). At therapeutic doses, propranolol is safe and effective in the majority of patients.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro, the antiangiogenic biological activity of propranolol was also shown to inhibit human brain microvascular endothelial cell tubulogenesis (Annabi et al 2009). Propranolol has recently been introduced as a pharmacologic treatment for infantile hemangiomas (Sidbury 2010;Storch and Hoeger 2010;Léauté-Labrèze et al 2008;Sarialioglu et al 2010;Sans et al 2009;Sommers Smith and Smith 2002;Love and Sikka 2004;Buckmiller et al 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Kozanoğlu

Yandım

Çinçin

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Propranolol, a non-selective b-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that b-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranololinduced apoptosis in multiple myeloma cells. Methods Time-dependent antiproliferation and apoptotic effects of propranolol were subsequently determined by MTT cell proliferation assay, changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and also the localization of phosphatidylserine in the plasma membrane. Changes in expression levels of NF-JB pathway were examined by qRT-PCR array.Results IC50 values of propranolol on U266 cells were calculated as 141, 100, and 75 lM after 24-, 48-, and 72-h propranolol exposure, respectively. There were significant increases in caspase-3 activity, loss of MMP, and increases in apoptotic cell population in response to propranolol in U266 cells in a time-and dose-dependent manner. There were increases in expression levels of BCL10, TRAF family members, interleukins, TLR1-4, TNFRSF10B, NFjB, and the inhibitors of NF-jB genes, and significant decreases in expression levels of Bcl-2 in response to propranolol treatment were observed. Conclusion These results revealed that propranolol has antiproliferative and apoptotic effects on multiple myeloma cells. Being supported with in vivo analyses, propranolol can be a good and economical way to treat multiple myeloma patients.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Kozanoğlu

Yandım

Çinçin

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…İHHE'nin tedavisinde öncelikle düşük, yanıt yoksa yüksek dozda steroid tercih edilir. Steroid ile kontrol altına alınamayan olgularda interferon-alfa kullanılır (17) . İHHE bazen de konjestif kalp yetmezliği/tüketim koagülopatisi vb.…”

Section: Discussionunclassified

Successful surgical treatment of an infant with infantile hepatic hemangioendothelioma

Özdemir¹,

Özdemir²,

Akın³

et al. 2012

TCCD

View full text Add to dashboard Cite

show abstract

“…Also, treatment of some complicated visceral hemangiomas with propranolol have been reported. 12,13,[20][21][22] Suggested therapeutic mechanism of propranolol was inhibition of angiogenesis and induction of apoptosis in endothelial cells. 23 Propranolol has been used for hemangiomas in our clinic since 2009.…”

Section: Discussionmentioning

confidence: 99%

Propranolol as a First-Line Treatment of Infantile Hemangioma: Single Center Experience

Ince¹,

Demirağ²,

Töret³

et al. 2015

Turkiye Klinikleri J Pediatr

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T OOb bj je ec ct ti iv ve e: : Infantile hemangiomas (IHs) are the most common benign vascular tumors in infancy. Spontaneous regression is expected in majority of IHs, so watchful waiting is the best management. Currently propranolol has taken the place of corticosteroids for the treatment of risky IHs. Herein we aimed to analyze our patients with IHs treated with propranolol. M Ma at te er ri ia al l a an nd d M Me et th h--o od ds s: There were 240 patients with diagnosis of IH, treatment was indicated in 11.3% (n:27) of them, and these 27 patients received propranolol as a first-line treatment between January 2012-January 2015. Medical records of these 27 patients were analized retrospectively. Clinical characteristics, physical examination findings, treatment indications, treatment details, responses and side effects of propranolol were analized retrospectively. R Re es su ul lt ts s: : The median age at diagnosis was 3 months (1-15), and M/F ratio was 0.23. The most common hemangioma localization was skin and head-neck region in 55.6% of patients. Treatment indications were local complications (haemorrhage, ulceration, infection) (44.4%), life threating organ dysfunction (33.3%) and relative indications (22.2%). The median follow-up period was 12 months (1-26 months). Pallor and partially regression in hemangiomas were observed between the fourth and sixth weeks in all patients. Complete remission occured in 15 patients, treatment is going on with partial remission in remaining 12 cases. There was no observed side effects of propranolol. C Co on nc cl lu us si io on n: : Propranolol is a well-tolerated, efficacious, and safe drug for treatment of IHs. It can be initiated and administered in the outpatient setting. Treatment indications of IHs may become more flexible taking into account of the safety profile of propranolol.K Ke ey y W Wo or rd ds s: : Hemangioma, capillary infantile; propranolol; treatment outcome Ö ÖZ ZE ET T A Am ma aç ç: : İnfantil hemanjiyomlar (İH) süt çocukluğu döneminin en sık karşılaşılan benign vasküler tümörleridir. Bu hastaların büyük bölümünde kendiliğinden gerileme beklenmektedir ve bu nedenle izleyerek beklemek en iyi yaklaşımdır. Günümüzde riskli IH tedavisinde kortikosteroidlerin yerini propranolol tedavisi almıştır. Biz burada IH tanısıyla izlediğimiz propranolol tedavisi uyguladığımız hastaları analiz ettik. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Ocak 2012-Ocak 2015 tarihleri arasında İH tanısı almış 240 hasta vardı, bunların %11,3 (n:27)'üne tedavi endikasyonu konmuştu ve ilk sıra tedavide propranolol verilmişti. Bu 27 hastanın tıbbi kayıtları retrospektif olarak incelendi. Klinik karakteristikler, fizik inceleme bulguları, tedavi endikasyonları, tedavi detayları, yanıtlar ve propranolol yan etkileri analiz edildi. B Bu ul lg gu ul la ar r: : Hastaların ortanca tanı yaşı 3 ay (1-15), E/K oranı 0,23 bulundu. Hemanjiyomun en sık lokalizasyonu deri ve baş boyun bölgesiydi (%55,6). Tedavi endikasyonları lokal komplikasyonlar (hemoraji,...

show abstract

Response of infantile hepatic hemangioma to propranolol resistant to high‐dose methylprednisolone and interferon‐α therapy

Cited by 39 publications

References 5 publications

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Successful surgical treatment of an infant with infantile hepatic hemangioendothelioma

Propranolol as a First-Line Treatment of Infantile Hemangioma: Single Center Experience

Contact Info

Product

Resources

About